Extended-interval tarlatamab dosing shows consistent activity and safety in previously treated small cell lung cancer

Extended-interval dosing regimens of tarlatamab demonstrated efficacy, information and pharmacokinetic profiles mostly accordant with the established every-two-week regimen successful patients with antecedently treated tiny compartment lung crab (SCLC), according to results from the randomized Phase II DeLLphi-309 survey presented astatine the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference connected Lung Cancer (WCLC).